Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 After Oral Administration (Randomized, Open-label, Two-treatment, Two-sequence, Two-period Crossover Study)

Trial Profile

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 After Oral Administration (Randomized, Open-label, Two-treatment, Two-sequence, Two-period Crossover Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs BI 409306 (Primary) ; Fluvoxamine (Primary)
  • Indications Alzheimer's disease; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 10 Jan 2017 Status changed from recruiting to completed.
    • 01 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 04 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top